Name of beneficiary
- University of Szeged
- 3DHISTECH Fejlesztő Ltd.
- Neumann Medical Ltd.
- PHARMAHUNGARY 2000 Kísérletes és Klinikai Kutatásfejlesztési Ltd.
National Cardiovascular Laboratory
Total financial support for consortium
5 670 176 720 Ft
Rate of support (percentage)
Project launch day
Planned project end-date
Neumann Medical Ltd. (previously Neumann Projekt és Szervezési Ltd.)
Company registration number
e1. floor, CityLab, 31, Tűzoltó street, H-1094 Budapest
Project ID number
Consortium partners and the funding shares
|Konzorciumi tag neve||Megítélt támogatás (Ft)||Önerő (Ft)||Összesen (Ft)|
|Semmelweis Egyetem||4 950 000 000 Ft||0 Ft||4 950 000 000 Ft|
|Neumann Medical Kft.||150 000 000 Ft||37 500 000 Ft||187 500 000 Ft|
Kísérletes és Klinikai
|149 999 999 Ft||32 676 721 Ft||182 676 720 Ft|
|Szegedi Tudományegyetem||50 000 000 Ft||0 Ft||50 000 000 Ft|
|3DHISTECH Fejlesztő Kft.||150 000 000 Ft||150 000 000 Ft||300 000 000 Ft|
The National Cardiovascular Laboratory will undertake a revolutionary approach to research into the pathophysiological mechanisms involved in the development of age-related cardiovascular diseases, with the aim of building on the results of this research to develop and implement new innovative preventive, diagnostic and therapeutic procedures.
Pillars of professional implementation:
The national laboratory programme will be based on the following main translational research projects, product and service development technical pillars.
1. Clinical – Epidemiological Programmes:
The programme will test the feasibility of implementing new procedures using an evidence-based indicator system in a cohort study (Semmelweis Study) at Semmelweis University. This study will embed the studies of the cardiovascular research programme of the Healthy Ageing Programme to be developed through the programme. The programme will research and develop innovative screening, diagnostic and therapeutic methods, services and products to reduce the incidence and mortality of ischaemic heart disease and heart failure. As part of the National Cardiovascular Laboratory’s clinical-epidemiological programmes, it will also map the potential medium- and long-term cardiovascular effects of COVID-19 infection through multimodal clinical and detailed follow-up. We plan to complete the international clinical trial BUDAPeST Upgrade CRT, the results of which will be used to develop new professional guidelines.
2. Innovative drug biotechnology development:
The National Cardiovascular Laboratory will explore new drug targets and repurpose existing drugs as part of its innovative drug biotechnology development programme. The analysis of gene and protein expression patterns in patient myocardial tissue will be performed through the development and application of integrative, network theory and artificial intelligence-based systems, resulting in the identification of new drug targets and drug repositioning improvements. Key elements of the programme include: development of in vitro cardiovascular platforms, further development of microRNA-based pharmacotherapeutic solutions, cardio-oncology trials, commercialisation of software to support RNA-based networked molecular bioinformatics drug development and drug safety improvements.
3. Development of innovative medical and diagnostic tools and databases:
As part of the National Cardiovascular Laboratory’s programmes for the development of innovative medical and diagnostic tools and databases, the identification and validation of extracellular vesicle-based diagnostic and therapeutic effect markers and measurement methods will be undertaken. The further development of software supporting structured annotation for “big data” network analysis will also be part of the programme. A laboratory test for biological ageing and associated software will also be introduced.
Expected results and impact:
The research results of the National Cardiovascular Laboratory will make a decisive contribution to the development of evidence-based cardiovascular health promotion and disease prevention programmes, helping to achieve the goal of enabling the country’s population to live healthy lives for longer and in old age. The interdisciplinary and translational nature of the programme will ensure its success in developing innovative evidence-based disease prevention, screening, diagnostic and therapeutic approaches to reduce the incidence and mortality of cardiovascular disease. The results of the programme will contribute to the international market penetration of innovative products and services with high economic added value, thereby supporting the development of the domestic pharmaceutical biotechnology industry.